Matches in DBpedia 2016-04 for { ?s ?p "MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- MBX-8025 abstract "MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.".
- Q17096822 abstract "MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.".
- MBX-8025 comment "MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.".
- Q17096822 comment "MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis. The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.".